Evidence map›Paper›PMID 40370857›Full record

ReviewRSC advances2025

Magnetic mesoporous silica nanoparticles as advanced polymeric scaffolds for efficient cancer chemotherapy: recent progress and challenges.

Sara Payamifar, Yasaman Khalili, Amin Foroozandeh, Majid Abdouss, Mohammad Hasanzadeh

Abstract readReview
In one paragraph

Review in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Mesoporous Silica Nanoparticles in Biomedicine: Advances and Prospects.Advanced materials (Deerfield Beach, Fla.) · 2026
    Review
  2. Latest Advancements in Using FeChemistryOpen · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sara PayamifarDepartment of Chemistry, Amirkabir University of Technology Tehran Iran aminforoozandeh94@gmail.com phdabdouss44@aut.ac.ir.
Yasaman KhaliliSchool of Chemistry, Faculty of Science, University of Tehran Iran.
Amin ForoozandehDepartment of Chemistry, Amirkabir University of Technology Tehran Iran aminforoozandeh94@gmail.com phdabdouss44@aut.ac.ir.
Majid AbdoussDepartment of Chemistry, Amirkabir University of Technology Tehran Iran aminforoozandeh94@gmail.com phdabdouss44@aut.ac.ir.
Mohammad HasanzadehPharmaceutical Analysis Research Center, Tabriz University of Medical Sciences Tabriz Iran hasanzadehm@tbzmed.ac.ir.ORCID https://orcid.org/0000-0003-4918-1239

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Magnetic mesoporous silica nanoparticles (MMS NPs) stand out as excellent options for targeted chemotherapy owing to their remarkable features, such as extensive surface area, substantial pore volume, adjustable and uniform pore size, facile scalability, and versatile surface chemistry. This review comprehensively explores the latest developments in MMS NPs, emphasizing their design, functionalization, and application in cancer therapy. Initially, we discuss the critical need for targeted and controlled drug delivery (DD) in oncology, highlighting the role of magnetic and MMs in addressing some challenges. Subsequently, the key features of MMS NPs, such as their high surface area, pore structure, and functionalization strategies, are examined for their impact on their DD performance for efficient cancer chemotherapy. The integration of chemotherapy methods such as photothermal therapy and photodynamic therapy with MMS NPs is also explored, showcasing multifunctional platforms that combine imaging and therapeutic capabilities. Finally, we identify the current challenges and provide future perspectives for the development and clinical translation of MMS NPs, underscoring their potential to reshape CT paradigms.

Identifiers

PMID40370857
PMCPMC12076205

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.